Previous close | 184.86 |
Open | 182.00 |
Bid | 0.00 x 800 |
Ask | 0.00 x 1000 |
Day's range | 172.19 - 183.40 |
52-week range | 132.24 - 243.52 |
Volume | |
Avg. volume | 1,030,470 |
Market cap | 25.568B |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 28.83 |
EPS (TTM) | 6.03 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | 1.92 (1.10%) |
Ex-dividend date | 07 Feb 2024 |
1y target est | 202.68 |
Eli Lilly stock popped Wednesday after the company's weight-loss drug significantly reduced nighttime sleep apnea events.
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: • Location:http://investor.resmed.com • Da
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, RMD, ZBH, PODD and LNTH are well-poised to gain from the favorable factors.